amarincorp.com (AMRN): Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization

Public company logo of amarincorp.com (AMRN)

Revenue declines due to pressure from competitors in the US are already priced in, yet threats of capital shortages and the loss of exclusive drug rights persist. This EV/EBITDA chart on GURU.Markets shows the current metric at 0.00. Amarin Corporation plc (AMRN), the developer of the cardiovascular drug Vascepa, is relying on seeking partners, new trials, and expansion into European countries to stimulate share price growth.

Amarin Corp - AMRN Total Company Value to Operating Income Before Depreciation Ratio (period 11/23/2025 - 11/15/2026)

Comprehensive metric breakdowns and analytics for Amarin (AMRN)

- current price and projected stock value:
Stock Price Amarin Pharma|AMRN - Analyst Consensus Forecast
- stock exchange capitalization data:
Market Value Amarin Corporation plc|AMRN - Value Adjusted for Debt and Cash
- book value of equity indicators:
Book Value per Share Amarin|AMRN - Book Valuation of Business|Market Value to Book Value Ratio amarincorp.com|AMRN - Total Business Assets
- debt and solvency information:
Total Debt to Equity Ratio Amarin Corporation plc|AMRN - Long-Term Debt to Capital Coefficient|Short-Term Debt to Capital Amarin Pharma|AMRN - Company Total Debt|Debt to Book Capitalization Ratio Amarin Pharma|AMRN - Long-Term Debt|Company Short-Term Debt Amarin|Quick Liquidity amarincorp.com
- financial results and valuation multiples details:
AMRN - Profit After Tax|Expected Profit Amarin Corporation plc|AMRN - Market Cap to Earnings|Future Price to Earnings Amarin|AMRN - Growth-Adjusted Payback Ratio|EV/EBITDA Multiple Amarin|AMRN - Operating profit EBITDA|Net earnings per share for the last 12 months Amarin|AMRN - Earnings per share for the last four quarters|Quarterly EPS earnings growth amarincorp.com|AMRN - Expected net earnings per share growth this year|Net earnings per share growth forecast for next year Amarin Corporation plc
- sales volume and revenue indicators:
AMRN - Company Total Revenue|Company Projected Revenue Amarin|AMRN - Market Cap to Revenue Ratio|Forward Price-to-Revenue Multiple Amarin Corporation plc
Analysis of all company metrics:AMRN (Amarin Corporation)
Manufactured products of amarincorp.com

Investors are evaluating Amarin Corporation plc (AMRN) through the lens of high dependency on a single drug amidst patent wars. The EV/EBITDA multiple compares enterprise value, including debt, with operating profit before taxes to reveal the asset's real value. Analyzing the EV/EBITDA trend of the business highlights how the risk of generic expansion impacts market expectations, allowing for the identification of the tipping point between fundamental undervaluation and unjustified optimism.

Competitor analysis

EV/EBITDA Multiple REGN (Regeneron Corp)|Business Value to Operating Income Before Depreciation IRTC|LNTH: Enterprise Value to EBITDA Ratio|Company Value to EBITDA Mineralys|HTFL (HeartFlow Corp) - Enterprise Value to EBITDA Ratio|Kestra - Business Value to Operating Income Before Depreciation|ESPR (esperion.com) - EV/EBITDA Multiple|Anteris Technologies (AVR) - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to EBITDA Ratio TNYA (Tenaya)|CVRx - Enterprise Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Milestone Pharmaceuticals MIST|Business Value to Operating Income Before Depreciation CRDL|BEAT - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to EBITDA tenaxthera.com|ADGM: EV/EBITDA Multiple|BioCardia - Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Catheter Precision Corp|EV/EBITDA Multiple arcabio.com|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Acasti Pharma Inc (ACST)|AVTE - Company Value to EBITDA|EV/EBITDA Multiple VERV (Verve Therapeutics, Inc.)|Business Value to Operating Income Before Depreciation WINT